The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
After finishing at $16.41 in the prior trading day, Zenas Biopharma Inc (NASDAQ: ZBIO) closed at $16.08, down -2.01%. In other words, the price has decreased by -$2.01 from its previous closing price. On the day, 0.53 million shares were traded. ZBIO stock price reached its highest trading level at $17.36 during the session, while it also had its lowest trading level at $15.9025.
Ratios:
Our goal is to gain a better understanding of ZBIO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 5.66 and its Current Ratio is at 5.66. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
On March 20, 2025, Wedbush started tracking the stock assigning a Outperform rating and target price of $35.
On February 04, 2025, Wolfe Research started tracking the stock assigning a Outperform rating and target price of $19.Wolfe Research initiated its Outperform rating on February 04, 2025, with a $19 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 07 ’26 when MOULDER LEON O JR bought 50,000 shares for $16.38 per share. The transaction valued at 819,000 led to the insider holds 316,155 shares of the business.
MOULDER LEON O JR bought 30,000 shares of ZBIO for $489,000 on Jan 08 ’26. The Chief Executive Officer now owns 346,155 shares after completing the transaction at $16.30 per share. On Jan 09 ’26, another insider, MOULDER LEON O JR, who serves as the Chief Executive Officer of the company, bought 20,000 shares for $16.55 each. As a result, the insider paid 331,000 and bolstered with 366,155 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ZBIO now has a Market Capitalization of 863161024 and an Enterprise Value of 573075008. For the stock, the TTM Price-to-Sale (P/S) ratio is 58.73 while its Price-to-Book (P/B) ratio in mrq is 3.46. Its current Enterprise Value per Revenue stands at 38.205 whereas that against EBITDA is -2.93.
Stock Price History:
The Beta on a monthly basis for ZBIO is -1.37, which has changed by 0.98029554 over the last 52 weeks, in comparison to a change of 0.19362879 over the same period for the S&P500. Over the past 52 weeks, ZBIO has reached a high of $44.60, while it has fallen to a 52-week low of $5.83. The 50-Day Moving Average of the stock is -53.15%, while the 200-Day Moving Average is calculated to be -17.49%.
Shares Statistics:
The stock has traded on average 635.00K shares per day over the past 3-months and 1584870 shares per day over the last 10 days, according to various share statistics. A total of 42.21M shares are outstanding, with a floating share count of 21.93M. Insiders hold about 59.14% of the company’s shares, while institutions hold 31.11% stake in the company. Shares short for ZBIO as of 1765756800 were 4950866 with a Short Ratio of 7.80, compared to 1763078400 on 4607781. Therefore, it implies a Short% of Shares Outstanding of 4950866 and a Short% of Float of 12.3.
